Next, 160 patient samples including primary ovarian cancers (n = 155), borderline tumours (n = 24) and recurrent ovarian cancers (n = 26) were immunohistochemically evaluated with HSP60. This evidence concerns the gene HSPD1 and ovarian cancer.